Company Chemomab Therapeutics Ltd.

Equities

CMMB

US16385C1045

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-24 pm EDT			5-day change	1st Jan Change
0.67 ^USD	0.00%		+13.56%	+31.37%

Apr. 10	Transcript : Chemomab Therapeutics Ltd. - Special Call
Mar. 07	Chemomab Therapeutics Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Managers	Title	Age	Since
Adi Mor CEO	Chief Executive Officer	43	11-09-21
Sigal Fattal DFI	Director of Finance/CFO	53	19-12-31
Matthew B. Frankel CTO	Chief Tech/Sci/R&D Officer	56	22-11-13
Ilan Vaknin CTO	Chief Tech/Sci/R&D Officer	-	22-08-11
Jack Lawler CTO	Chief Tech/Sci/R&D Officer	-	22-01-03
Barbara Lindheim IRC	Investor Relations Contact	-	-
Sharon Hashmueli LAW	General Counsel	-	15-12-31

Members of the board	Title	Age	Since
Neil Cohen BRD	Director/Board Member	60	20-03-31
Nissim Darvish CHM	Chairman	59	21-03-15
Claude Nicaise BRD	Director/Board Member	71	21-03-15
Alan Moses BRD	Director/Board Member	76	21-03-15
Adi Mor CEO	Chief Executive Officer	43	11-09-21
Jill Quigley BRD	Director/Board Member	48	22-06-20

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	20	14,204,735	705,422 ( 4.966 %)	0	4.966 %

Name	Equities	%	Valuation
OrbiMed Advisors Private Equity 16.45 %	2,241,274	16.45 %	2 M $
Ikarian Capital LLC 1.566 %	213,392	1.566 %	166 232 $
Morgan Stanley Capital Services LLC 0.5206 %	70,915	0.5206 %	55 243 $
Two Sigma Investments LP 0.4133 %	56,305	0.4133 %	43 862 $
Two Sigma Advisers LP 0.2599 %	35,400	0.2599 %	27 577 $
Citadel Securities GP LLC 0.2399 %	32,677	0.2399 %	25 455 $
Kestra Private Wealth Services LLC 0.2293 %	31,241	0.2293 %	24 337 $
XTX Topco Ltd. 0.2132 %	29,047	0.2132 %	22 628 $
Boothbay Fund Management LLC 0.1947 %	26,529	0.1947 %	20 666 $
Virtu Financial LLC 0.1894 %	25,808	0.1894 %	20 104 $

Name	Equities	%	Valuation
Peter Thiel 10.36 %	22,170,180	10.36 %	863 529 $
Apeiron Investment Group Ltd. /Private Equity/ 0.3399 %	727,163	0.3399 %	28 323 $
Centillion Fund, Inc. 0.3091 %	661,370	0.3091 %	25 760 $
Adi Mor 0.2656 %	568,222	0.2656 %	22 132 $
Neil Cohen 0.0707 %	151,218	0.0707 %	5 890 $
Sigal Fattal 0.007012 %	15,002	0.007012 %	584 $
Dale Pfost 0.001168 %	2,500	0.001168 %	97 $
Donald Marvin 0.000935 %	2,000	0.000935 %	78 $
Nissim Darvish 0.000561 %	1,200	0.000561 %	47 $
Claude Nicaise 0.000000 %	0	0.000000 %	- $

Chemomab Therapeutics Ltd.

Kiryat Atidim Building 7

6158002, Tel Aviv

+972 77 331 0156

http://www.chemomab.com

address Chemomab Therapeutics Ltd.(CMMB)

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.67 USD

Average target price

7 USD

Spread / Average Target

+944.78%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
CHEMOMAB THERAPEUTICS LTD.	+31.37%	9.52M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+0.99%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-8.65%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B

Bio Therapeutic Drugs